Topics:
Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • Yale • Fertility Preservation • NCI-CCC Breast Tumor Board Question • Pregnancy • Breast Cancer, Non-metastatic • Endocrinology
Do you offer adjuvant bisphosphonates to high-risk premenopausal women on ovarian suppression for early-stage breast cancer who would want to consider pregnancy in the future?
Which agents would you select and for how long would you treat them?
Answer from: Medical Oncologist at Academic Institution
ASCO guidelines from 1/2022 recommend a discussion of bisphosphonate therapy in post-menopausal women or women on ovarian suppression who are candidates for adjuvant therapy, but risks and benefits should be carefully weighed.In a large meta-analysis of adjuvant bisphosphonate therapy in early breas...
Sign in or Register to read more